Cargando…
“Repurposing” Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years’ Experience in One Medical Practice
A total of 71 patients with Lyme disease were identified for analysis in whom treatment with disulfiram was initiated between 15 March 2017 and 15 March 2020. Four patients were lost to follow-up, leaving 67 evaluable patients. Our retrospective review found patients to fall into a “high-dose” group...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761882/ https://www.ncbi.nlm.nih.gov/pubmed/33291557 http://dx.doi.org/10.3390/antibiotics9120868 |
_version_ | 1783627672639766528 |
---|---|
author | Gao, Jiachen Gong, Zhaodi Montesano, Dawn Glazer, Erica Liegner, Kenneth |
author_facet | Gao, Jiachen Gong, Zhaodi Montesano, Dawn Glazer, Erica Liegner, Kenneth |
author_sort | Gao, Jiachen |
collection | PubMed |
description | A total of 71 patients with Lyme disease were identified for analysis in whom treatment with disulfiram was initiated between 15 March 2017 and 15 March 2020. Four patients were lost to follow-up, leaving 67 evaluable patients. Our retrospective review found patients to fall into a “high-dose” group (≥4 mg/kg/day) and a “low-dose” group (<4 mg/kg/day). In total, 62 of 67 (92.5%) patients treated with disulfiram were able to endorse a net benefit of the treatment with regard to their symptoms. Moreover, 12 of 33 (36.4%) patients who completed one or two courses of “high-dose” therapy enjoyed an “enduring remission”, defined as remaining clinically well for ≥6 months without further anti-infective treatment. The most common adverse reactions from disulfiram treatment in the high-dose group were fatigue (66.7%), psychiatric symptoms (48.5%), peripheral neuropathy (27.3%), and mild to moderate elevation of liver enzymes (15.2%). We observed that although patients on high dose experienced a higher risk for adverse reactions than those on a low dose, high-dose patients were significantly more likely to achieve enduring remission. |
format | Online Article Text |
id | pubmed-7761882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77618822020-12-26 “Repurposing” Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years’ Experience in One Medical Practice Gao, Jiachen Gong, Zhaodi Montesano, Dawn Glazer, Erica Liegner, Kenneth Antibiotics (Basel) Article A total of 71 patients with Lyme disease were identified for analysis in whom treatment with disulfiram was initiated between 15 March 2017 and 15 March 2020. Four patients were lost to follow-up, leaving 67 evaluable patients. Our retrospective review found patients to fall into a “high-dose” group (≥4 mg/kg/day) and a “low-dose” group (<4 mg/kg/day). In total, 62 of 67 (92.5%) patients treated with disulfiram were able to endorse a net benefit of the treatment with regard to their symptoms. Moreover, 12 of 33 (36.4%) patients who completed one or two courses of “high-dose” therapy enjoyed an “enduring remission”, defined as remaining clinically well for ≥6 months without further anti-infective treatment. The most common adverse reactions from disulfiram treatment in the high-dose group were fatigue (66.7%), psychiatric symptoms (48.5%), peripheral neuropathy (27.3%), and mild to moderate elevation of liver enzymes (15.2%). We observed that although patients on high dose experienced a higher risk for adverse reactions than those on a low dose, high-dose patients were significantly more likely to achieve enduring remission. MDPI 2020-12-04 /pmc/articles/PMC7761882/ /pubmed/33291557 http://dx.doi.org/10.3390/antibiotics9120868 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gao, Jiachen Gong, Zhaodi Montesano, Dawn Glazer, Erica Liegner, Kenneth “Repurposing” Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years’ Experience in One Medical Practice |
title | “Repurposing” Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years’ Experience in One Medical Practice |
title_full | “Repurposing” Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years’ Experience in One Medical Practice |
title_fullStr | “Repurposing” Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years’ Experience in One Medical Practice |
title_full_unstemmed | “Repurposing” Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years’ Experience in One Medical Practice |
title_short | “Repurposing” Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years’ Experience in One Medical Practice |
title_sort | “repurposing” disulfiram in the treatment of lyme disease and babesiosis: retrospective review of first 3 years’ experience in one medical practice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761882/ https://www.ncbi.nlm.nih.gov/pubmed/33291557 http://dx.doi.org/10.3390/antibiotics9120868 |
work_keys_str_mv | AT gaojiachen repurposingdisulfiraminthetreatmentoflymediseaseandbabesiosisretrospectivereviewoffirst3yearsexperienceinonemedicalpractice AT gongzhaodi repurposingdisulfiraminthetreatmentoflymediseaseandbabesiosisretrospectivereviewoffirst3yearsexperienceinonemedicalpractice AT montesanodawn repurposingdisulfiraminthetreatmentoflymediseaseandbabesiosisretrospectivereviewoffirst3yearsexperienceinonemedicalpractice AT glazererica repurposingdisulfiraminthetreatmentoflymediseaseandbabesiosisretrospectivereviewoffirst3yearsexperienceinonemedicalpractice AT liegnerkenneth repurposingdisulfiraminthetreatmentoflymediseaseandbabesiosisretrospectivereviewoffirst3yearsexperienceinonemedicalpractice |